Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2023-05-10 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于调整2022年度利润分配方案每股分配比例的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from the company 圣湘生物科技股份有限公司 regarding an adjustment to the 2022 annual profit distribution plan, specifically the per-share cash dividend amount. It details the reason for the adjustment, related to share repurchases affecting the number of shares entitled to dividends, and recalculates the dividend per share accordingly. The document does not contain full financial statements or comprehensive financial performance data, but rather focuses on dividend distribution details. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related shareholder details.
2023-05-10 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2022年年度股东大会的法律意见书
Regulatory Filings
2023-05-09 Chinese
圣湘生物科技股份有限公司关于2023年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Director's Dealing Classification · 95% confidence The document is a self-inspection report regarding insider trading related to a 2023 restricted stock incentive plan. It details the investigation of stock transactions by insiders during a specific period and concludes no insider trading occurred. The document is a regulatory announcement about compliance and insider trading checks, not a financial report, earnings release, or management discussion. It does not contain financial statements or results but is a compliance disclosure related to insider dealings. Therefore, it fits best under Director's Dealing (DIRS) as it reports on insider share transactions and compliance with insider trading regulations.
2023-05-09 Chinese
圣湘生物科技股份有限公司2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the resolutions from the 2022 Annual General Meeting (AGM) of 圣湘生物科技股份有限公司. It details the meeting date, attendance, voting results on various proposals including the 2022 annual report, profit distribution, board work report, auditor appointment, and stock incentive plans. The document is a formal announcement of the voting results and meeting proceedings rather than the full annual report or detailed financial statements. It includes voting percentages and confirms the legality and validity of the meeting and resolutions. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings. The document length (7208 characters) and content confirm it is not a brief report publication announcement or a full annual report but a detailed voting result announcement from the AGM.
2023-05-09 Chinese
圣湘生物科技股份有限公司关于对外投资暨关联交易的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about an external investment and related party transaction by 圣湘生物科技股份有限公司. It includes comprehensive information about the investment structure, the target company, valuation, strategic rationale, and risk factors. The content focuses on a specific capital investment transaction and its implications for the company, rather than presenting financial statements or earnings data. There is no indication that this is a full annual or interim report, audit report, earnings release, or other financial report. The document is not a brief announcement or a report publication notice but a substantive disclosure about financing and capital investment activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-05-09 Chinese
圣湘生物科技股份有限公司独立董事关于第二届董事会2023年第六次临时会议相关事宜的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinion on a specific board meeting agenda item related to external investment and related party transactions. It references compliance with stock exchange rules and laws but does not contain financial statements, audit results, or detailed financial data. The document is short (446 characters) and serves as a formal opinion or announcement related to board management matters. It does not fit categories like Annual Report, Interim Report, or Audit Report. It is best classified under Board/Management Information (MANG) as it concerns board meeting matters and independent directors' opinions on company decisions.
2023-05-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.